"Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
"Prof. Dr. N. Oblu" Emergency Clinical Hospital, 700309 Iasi, Romania.
Int J Mol Sci. 2022 Jun 9;23(12):6460. doi: 10.3390/ijms23126460.
Low back pain (LBP) represents a frequent and debilitating condition affecting a large part of the global population and posing a worldwide health and economic burden. The major cause of LBP is intervertebral disc degeneration (IDD), a complex disease that can further aggravate and give rise to severe spine problems. As most of the current treatments for IDD either only alleviate the associated symptoms or expose patients to the risk of intraoperative and postoperative complications, there is a pressing need to develop better therapeutic strategies. In this respect, the present paper first describes the pathogenesis and etiology of IDD to set the framework for what has to be combated to restore the normal state of intervertebral discs (IVDs), then further elaborates on the recent advances in managing IDD. Specifically, there are reviewed bioactive compounds and growth factors that have shown promising potential against underlying factors of IDD, cell-based therapies for IVD regeneration, biomimetic artificial IVDs, and several other emerging IDD therapeutic options (e.g., exosomes, RNA approaches, and artificial intelligence).
下背痛(LBP)是一种常见且使人虚弱的病症,影响了全球很大一部分人群,给全球的健康和经济带来了负担。LBP 的主要病因是椎间盘退行性病变(IDD),这是一种复杂的疾病,可进一步加重并导致严重的脊柱问题。由于目前大多数 IDD 的治疗方法要么只能缓解相关症状,要么使患者面临术中及术后并发症的风险,因此迫切需要开发更好的治疗策略。在这方面,本文首先描述了 IDD 的发病机制和病因,为恢复椎间盘正常状态(IVD)必须要对抗的因素奠定了框架,然后进一步阐述了管理 IDD 的最新进展。具体来说,本文综述了具有潜在抗 IDD 潜在因素的生物活性化合物和生长因子、用于 IVD 再生的细胞疗法、仿生人工 IVD 和其他几种新兴的 IDD 治疗选择(例如外泌体、RNA 方法和人工智能)。